Murali Kesavan

474 total citations
22 papers, 219 citations indexed

About

Murali Kesavan is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Murali Kesavan has authored 22 papers receiving a total of 219 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 5 papers in Genetics. Recurrent topics in Murali Kesavan's work include Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Lung Cancer Research Studies (5 papers). Murali Kesavan is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Lung Cancer Research Studies (5 papers). Murali Kesavan collaborates with scholars based in Australia, United Kingdom and United States. Murali Kesavan's co-authors include J. Harvey Turner, Phillip G. Claringbold, Toby A. Eyre, Graham P. Collins, Giuseppe Cardaci, Danielle Meyrick, Nat Lenzo, Wei‐Sen Lam, W A Macdonald and R Kuttan and has published in prestigious journals such as Blood, BMC Cancer and Frontiers in Oncology.

In The Last Decade

Murali Kesavan

20 papers receiving 213 citations

Peers

Murali Kesavan
Xu-Bao Liu China
Reynolds Jc United States
Sophie Dominguez France
Hans H G Verbeek Netherlands
Ivana Puliafito Italy
Ángel Castaño Spain
Areen Said United States
Jietian Jin China
Apostolos Koffas United Kingdom
Xu-Bao Liu China
Murali Kesavan
Citations per year, relative to Murali Kesavan Murali Kesavan (= 1×) peers Xu-Bao Liu

Countries citing papers authored by Murali Kesavan

Since Specialization
Citations

This map shows the geographic impact of Murali Kesavan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murali Kesavan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murali Kesavan more than expected).

Fields of papers citing papers by Murali Kesavan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murali Kesavan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murali Kesavan. The network helps show where Murali Kesavan may publish in the future.

Co-authorship network of co-authors of Murali Kesavan

This figure shows the co-authorship network connecting the top 25 collaborators of Murali Kesavan. A scholar is included among the top collaborators of Murali Kesavan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murali Kesavan. Murali Kesavan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yüce, Anıl, Christian Doerig, Agata Mosinska, et al.. (2024). Deep Learning Predicts Risk of Large B-Cell Lymphoma Progression upon R-CHOP Therapy from Baseline Histology. Blood. 144(Supplement 1). 108–108.
2.
Diefenbach, Catherine, Andrew D. Zelenetz, Charles Herbaux, et al.. (2024). Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma. Blood. 144(Supplement 1). 577–577. 2 indexed citations
3.
Appleby, Niamh, et al.. (2022). Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome. Frontiers in Oncology. 12. 888109–888109. 5 indexed citations
4.
Kesavan, Murali & J. Harvey Turner. (2021). Myeloid Toxicity of Radionuclide Cancer Therapy. Cancer Biotherapy and Radiopharmaceuticals. 37(3). 164–172. 2 indexed citations
5.
6.
7.
Kesavan, Murali, et al.. (2021). Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET. Endocrine Related Cancer. 28(7). 521–527. 19 indexed citations
8.
Kesavan, Murali, Toby A. Eyre, & Graham P. Collins. (2019). Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma. Current Hematologic Malignancy Reports. 14(4). 207–218. 14 indexed citations
9.
Sahoo, Dipak Kumar, et al.. (2019). Sub-chronic Indoxacarb-induced haemato-biochemical and histopathological changes in rats. Indian Journal of Veterinary Pathology. 43(1). 43–43. 1 indexed citations
10.
Advani, Ranjana H., Nancy L. Bartlett, Mark Roschewski, et al.. (2019). S867 THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS. HemaSphere. 3(S1). 388–388. 2 indexed citations
11.
Kesavan, Murali, et al.. (2019). Peripheral T cell lymphoma (PTCL) in children and adolescents – a single centre experience. Pediatric Hematology Oncology Journal. 4(2). S29–S29.
12.
Kesavan, Murali, et al.. (2018). Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice. Cancer Biotherapy and Radiopharmaceuticals. 33(7). 274–281. 21 indexed citations
13.
Kesavan, Murali, et al.. (2018). Flow cytometry based initial therapy in mixed phenotypic acute leukemia in children– fifteen year follow up study from a single center in India. Pediatric Hematology Oncology Journal. 3(3). S2–S3. 1 indexed citations
14.
Kesavan, Murali, et al.. (2018). Treosulfan Based Conditioning Regimen – Reduced Toxicity With Excellent Outcomes In Children With Primary Immune Deficiency. Pediatric Hematology Oncology Journal. 3(3). S32–S32. 1 indexed citations
15.
16.
Kesavan, Murali & J. Harvey Turner. (2016). Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience. Cancer Biotherapy and Radiopharmaceuticals. 31(6). 189–198. 53 indexed citations
17.
Kesavan, Murali, et al.. (2015). Effect of preoperative pregabalin on postoperative pain relief in thyroidectomy patients: A prospective observational study. Anesthesia Essays and Researches. 9(2). 161–161. 15 indexed citations
18.
Kesavan, Murali, Phillip G. Claringbold, & J. Harvey Turner. (2014). Hematological Toxicity of Combined <sup>177</sup>Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up. Neuroendocrinology. 99(2). 108–117. 53 indexed citations
19.
Kesavan, Murali, et al.. (1990). Clinical trial of certain ayurvedic medicines indicated in vitiligo.. PubMed. 9(4). 202–6. 7 indexed citations
20.
Kesavan, Murali, et al.. (1989). Anti-cancer activity of nigella sativa.. PubMed. 8(3-4). 262–6. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xu-Bao Liu Breakdown of academic impact, for papers by Reynolds Jc Breakdown of academic impact, for papers by Sophie Dominguez Breakdown of academic impact, for papers by Hans H G Verbeek Breakdown of academic impact, for papers by Ivana Puliafito Breakdown of academic impact, for papers by Ángel Castaño Breakdown of academic impact, for papers by Areen Said Breakdown of academic impact, for papers by Jietian Jin Breakdown of academic impact, for papers by Apostolos Koffas
Rankless by CCL
2026